Picture courtesy The News Minute
New Delhi: The supply price of COVID-19 vaccine Covaxin to the Central government at Rs 150 per dose is not sustainable in the long run, Bharat Biotech said on Tuesday.
The Centre’s supplying price is pushing the pricing structure for the private sector upward, the vaccine maker said, justifying Covaxin’s higher price when compared to other COVID-19 vaccines available for the private sector in India.
According to the company, fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among others were contributing to higher pricing of Covaxin.
“The supply price of Covaxin to the government of India at Rs 150 per dose is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs,” Bharat Biotech said in a statement.
Cuttack: A promising youthful life ended in Cuttack on Sunday as a sophomore was electrocuted…
Mumbai: Ever since ‘Kantara’ became a phenomenal hit in 2022, movie lovers have been yearning…
Bhubaneswar: The husband of a sarpanch and a panchayat samiti member were critically injured as…
New Delhi: Pollution in the national Capital is going from bad to worse. As Delhi’s air…
Bhubaneswar: In order to streamline the road construction works, the Odisha government is planning to…
Patna: The trailer of ‘Pushpa 2: The Rule’, one of the year’s most anticipated films, is…
Patna: It was one of the most anticipated events in the Indian film industry -- the…
Bhubaneswar: With Odisha government taking a serious note of unnatural death of elephants, the Forest…